Biophytis S.A. (EPA:ALBPS)
France · Delayed Price · Currency is EUR | Market Cap | 14.88M +523.3% |
| Revenue (ttm) | n/a |
| Net Income | -8.03M |
| EPS | -0.61 |
| Shares Out | 350.10M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,402,511 |
| Open | 0.0418 |
| Previous Close | 0.0411 |
| Day's Range | 0.0401 - 0.0429 |
| 52-Week Range | 0.0042 - 0.1600 |
| Beta | 1.84 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Mar 12, 2027 |
About Biophytis
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company’s lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the develop... [Read more]
Financial Performance
Financial StatementsNews
Biophytis Targets Mobility Restoration in Patients with Obesity
Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - April 22, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in develop...
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - April 9, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the dev...
Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity
96% of patients with obesity report experiencing muscle strength impairment, affecting their mobility New preclinical study results: The combination of BIO101 and GLP-1 induced muscle strength and mob...
Biophytis Revolutionizes Sarcopenia
Publication of SARA-INT Phase II results for BIO101 Confirmation of Phase 3 readiness Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - March 17, 2025) - Biophytis SA (FP: ALBPS) ("Biophyt...
Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)
Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - February 25, 2025) - Biophytis SA (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the ...
Biophytis Unveils Its Outlook Strategies for 2025
Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - February 11, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the ...
Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference
Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - January 27, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the d...
Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China
Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - January 21, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the d...
Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101
Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - January 14, 2025) - Biophytis SA (OTC Pink: BPTSY) (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company spec...
Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on develop...
Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 22, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the de...
Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 11, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the dev...
Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 1, 2024 / Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the de...
Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million
Biophytis to receive upfront and milestones payments for a total amount up to €108 million, as well as double-digit royaltieson future sales of the product Agreement covers commercialization of BIO101...
Biophytis Extends Its Contract With Atlas to Secure Financing for Its Business Activities
Important note: Biophytis has set up financing in the form of Bonds redeemable in cash and in new and existing shares (ORNANE) with the company Atlas, which, after having received the shares resulting...
Biophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider Seqens
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 12, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the dev...
Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the dev...
Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 14, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the deve...
Biophytis is Deploying its Partnership Strategy in Obesity
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 29, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the de...
Biophytis Announces Transfer of ADSs to OTC Market
ADSs delisted from Nasdaq, which will result in meaningful savings ADSs transferred to OTC Pink market; Company will apply to trade on OTCQB market Biophytis remains listed on Euronext Growth Paris as...
Biophytis SA (ADR) trading halted, news pending
19:50 EDT Biophytis SA (ADR) trading halted, news pending
Biophytis launches OBA phase 2 clinical study in obesity with BIO101
Biophytis SA announced that it is launching a new clinical development program named OBA, with BIO101 as a potential treatment for obesity in combination with GLP-1 receptor agonists. Obesity treatmen...
Biophytis receives notice of delisting from Nasdaq, will request hearing
Biophytis announces that it has received a notice of delisting from Nasdaq. The staff of the Listing Qualifications Department has determined that the company’s securities have not regained compliance...
Biophytis downgraded to Reduce from Hold at Kepler Cheuvreux
Kepler Cheuvreux downgraded Biophytis to Reduce from Hold with a EUR 0.01 price target.
Biophytis approved by FDA to initiate SARA-31 Phase 3 study in sarcopenia
Biophytis announced that it has received FDA authorization to launch its SARA-31 study in the US, the first ever phase 3 study in sarcopenia. This authorization complements the positive opinion…